Table 4.
Summary of the secondary outcomes.
| Secondary outcomes | Number of studies | CRT + AVJA, n | CRT, n | Model | Mean difference | 95% CI |
PHet | PE | P | |
|---|---|---|---|---|---|---|---|---|---|---|
| Lower limit | Upper limit | |||||||||
| Biventricular pacing rate | 6 | 978 | 1528 | Random | 8.65 | 5.62 | 11.67 | <0.01 | 0.19 | <0.01 |
| Improvement of LVEF | 8 | 280 | 399 | Random | 1.43 | -4.88 | 7.74 | < 0.01 | 0.49 | 0.66 |
| Reduction of LVEDD | 4 | 78 | 249 | Random | -2.11 | -3.79 | -0.42 | 0.07 | 0.25 | 0.01 |
| Improvement of NYHA functional class | 5 | 102 | 182 | Random | -0.12 | -0.41 | 0.17 | < 0.01 | 0.97 | 0.43 |
| Improvement of walking distance in SMWT | 4 | 107 | 209 | Fixed | 32.95 | -0.46 | 66.37 | 0.31 | 0.63 | 0.05 |
| Improvement of MLHFQ | 3 | 88 | 102 | Fixed | -1.82 | -8.5 | 4.87 | 0.33 | 0.37 | 0.59 |
AVJA = atrioventricular junction ablation; CRT = cardiac resynchronization therapy; CI = confidence interval; LVEDD = left ventricular end-diastolic diameter; LVEF = left ventricular ejection fraction; MLHFQ = Minnesota living with heart failure questionnaire; NYHA = New York Heart Association; SMWT = six-minute wak test; PE = P Egger; PHet = P for heterogeneity.